Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
EQ
$1.92
$
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Next Earnings
2026-02-25
Beta
1.846
Average Volume
Market Cap
Last Dividend
CIK
0001746466
ISIN
US29446K1060
CUSIP
29446K106
CEO
Bruce D. Steel
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
35
IPO Date
2018-10-12
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Short Interest in Equillium, Inc. (NASDAQ:EQ) Increases By 32.2% | Equillium, Inc. (NASDAQ: EQ - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 1,473,443 shares, a growth of 32.2% from the December 31st total of 1,114,202 shares. Approximately 3.5% of the shares of the stock are sold | Defense World | 2026-02-04 04:35:03 |
| Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. | GlobeNewsWire | 2026-02-02 16:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| SC 13G/A | 2026-02-06 | 2026-02-06 | View Filing |
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-15 | 2025-12-15 | View Filing |
| SC 13G | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| S-3 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K/A | 2025-10-24 | 2025-10-24 | View Filing |
| 8-K | 2025-10-06 | 2025-10-06 | View Filing |
| 8-K | 2025-09-19 | 2025-09-19 | View Filing |
| 424B5 | 2025-09-19 | 2025-09-19 | View Filing |
| EFFECT | 2025-09-19 | 2025-09-19 | View Filing |
| S-8 | 2025-09-09 | 2025-09-09 | View Filing |
| S-3 | 2025-09-09 | 2025-09-09 | View Filing |
| 8-K | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-04 | 2025-08-04 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-22 | 2025-05-22 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| DEFR14A | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-04-24 | 2025-04-24 | View Filing |
| ARS | 2025-04-10 | 2025-04-10 | View Filing |
| DEFA14A | 2025-04-10 | 2025-04-10 | View Filing |
| DEF 14A | 2025-04-10 | 2025-04-10 | View Filing |
| PRE 14A | 2025-03-28 | 2025-03-28 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-12 | 2024-12-12 | View Filing |
| 3 | 2024-12-12 | 2024-12-12 | View Filing |
| 8-K | 2024-12-12 | 2024-12-12 | View Filing |
| 4 | 2024-11-15 | 2024-11-15 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-10-31 | 2024-10-31 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 8-K | 2024-10-31 | 2024-10-30 | View Filing |
| 4 | 2024-10-29 | 2024-10-29 | View Filing |
| 4 | 2024-09-27 | 2024-09-27 | View Filing |
| 4 | 2024-09-17 | 2024-09-17 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-07-23 | 2024-07-23 | View Filing |
| 4 | 2024-07-18 | 2024-07-18 | View Filing |
| 8-K | 2024-07-18 | 2024-07-18 | View Filing |
| 8-K | 2024-06-04 | 2024-06-04 | View Filing |
| 4 | 2024-05-23 | 2024-05-23 | View Filing |
| 4 | 2024-05-23 | 2024-05-23 | View Filing |
| 4 | 2024-05-23 | 2024-05-23 | View Filing |
| 4 | 2024-05-23 | 2024-05-23 | View Filing |
| 4 | 2024-05-23 | 2024-05-23 | View Filing |
| 4 | 2024-05-23 | 2024-05-23 | View Filing |
| 8-K | 2024-05-23 | 2024-05-23 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| ARS | 2024-04-11 | 2024-04-11 | View Filing |
| DEFA14A | 2024-04-11 | 2024-04-11 | View Filing |
| DEF 14A | 2024-04-11 | 2024-04-11 | View Filing |
| PRE 14A | 2024-04-01 | 2024-04-01 | View Filing |
| 8-K | 2024-04-01 | 2024-04-01 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 66.36% | 1.01 | 362 | 0.04 | 0.1 | 75.35 |
| Neural Forcast | 66.28% | 1 | 786 | 0.02 | 0.05 | 75.27 |
| Quantum Inspired Strategy | 26.56% | 1.01 | 417 | 0.01 | 0.04 | 35.55 |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxx% | xxxx | x | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |